Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of GM1 sodium injection (Shenjie) for Parkinson's disease with motor fluctuations
CTR20261468Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of monosialotetrahexosylganglioside in Parkinson's disease (PD), sponsored by Qilu Pharmaceutical. Started Apr 2026; status: active.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20261468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261468.